ClinicalTrials.gg
RecruitingNCT06223568Updated Nov 16, 2026

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

A Phase 2 interventional study of Docetaxel and Cisplatin in Squamous Cell Carcinoma of the Head and Neck, Oropharynx and Human Papillomavirus Viruses, sponsored by National Cancer Institute (NCI). Recruiting at 1 site in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by National Cancer Institute (NCI) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.
Updated Oct 16, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Squamous Cell Carcinoma of Head and Neck by National Cancer Institute (NCI) — 8 open to participants now, 17 under way, 4 of them phase 3. Squamous Cell Carcinoma of Head and Neck · National Cancer Institute (NCI).

Planned enrollment
17th of 70
70 · median 40
Started
2024
the only one that year
Phase 2
34 of 76
5 open now
Primary completion
2028-01
later than 12 of 16 live
Registered
72nd of 76
by date

Among the 76 studies in Squamous Cell Carcinoma of Head and Neck by National Cancer Institute (NCI), this one is the 17th largest by planned enrollment of the 70 interventional ones that give a count, is the only one that started in 2024, is one of 34 in phase 2, reaches primary completion later than 12 of the 16 other live ones, and was the 72nd registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

8 of the 76 studies in Squamous Cell Carcinoma of Head and Neck by National Cancer Institute (NCI) are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Squamous Cell Carcinoma of Head and Neck by National Cancer Institute (NCI), or all of them as a file.
02

Study summary

Background:

Throat cancer is a common tumor that can occur in people infected with the human papilloma virus (HPV). Most people with this cancer survive more than 5 years with standard chemotherapy drugs plus radiation. But radiation can cause serious adverse effects. Researchers believe that adding a vaccine (PRGN-2009) to this drug therapy may improve survival without the need for radiation.

Objective:

To test a study vaccine combined with standard chemotherapy in patients with HPV-associated throat cancers.

Eligibility:

People aged 18 years and older with newly diagnosed throat cancer associated with HPV.

Design:

Participants will be screened. They will have a physical exam and blood tests. They will have imaging scans and tests of their heart function and hearing. They will provide a sample of tissue from their tumor. A recent sample may be used; if none is available, a new sample will be taken.

All participants will get two common drugs for treating cancer. These drugs are given through a tube attached to a needle inserted into a vein in the arm. Participants will receive these drugs on the first day of three 3-week cycles.

Half of the participants will also get the vaccine. PRGN-2009 is injected under the skin in the arm. They will get these shots 4 times: 7 days before the start of the first cycle and on the 11th day of each cycle.

Participants will have standard surgery to remove their tumors 3 to 6 weeks after completing the study treatment. They will have follow-up visits 3, 6, 12, and 24 months after their surgery. Participants will then be contacted by phone once every year for 3 years.

...

Read the detailed description

Background:

  • Human papilloma virus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is among the most common HPV-associated malignancies and the incidence is increasing. The prognosis is favorable with >80% 5-year recurrence free survival observed following standard anti-cancer treatments that consist of surgery followed by adjuvant post-operative radiation therapy (PORT) or concurrent chemoradiation (CRT).
  • Although oncologic control is excellent, these standard-of-care treatments often lead to radiation-associated long-term toxicity that includes tissue fibrosis resulting in long-term swallow dysfunction and poor quality of life (QOL).
  • Neoadjuvant chemotherapy (NAC) followed by surgery has decades of real-world data, with clinical-to-pathologic downstaging or pathologic complete response (pCR) being observed in most patients, >90% 5-year survival, and complete avoidance of radiation treatment in >95% of patients.
  • The rate of pCR, clinical-to-pathologic downstaging, and functional outcomes after NAC followed by surgery have not been studied in a formal, prospective clinical study.
  • A pilot correlative study of NAC with docetaxel and cisplatin (DC) in patients with newly diagnosed HPV-associated OPSCC conducted at the NIH revealed induction of HPV-specific T cell immunity that associates with clinical outcome (18DC0051).
  • PRGN-2009 is a gorilla adenoviral therapeutic vaccine designed to enhance HPV 16/18- specific T-cell responses. The safety and efficacy of PRGN-2009 in patients with newly diagnosed HPV-associated OPSCC have been studied at the NIH Clinical Center (NCT04432597).
  • Pre-clinical data indicate that chemotherapy can remodel the tumor microenvironment and enhance immunotherapy, suggesting that the combination of DC and PRGN-2009 may enhance anti-tumor immunity and the rate of pCR beyond that observed with DC alone.

Objective:

-To determine the rate of pCR with NAC (DC) alone or in combination with PRGN-2009 (DCP) in participants with newly diagnosed HPV-associated OPSCC.

Eligibility criteria:

  • Pathologically confirmed newly diagnosed surgically resectable stage I or II HPV-positive oropharyngeal squamous cell carcinoma.
  • Age >= 18 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status \<= 2 and adequate organ function.

Design:

  • Participants diagnosed in the community with newly diagnosed HPV-associated OPSCC will be referred to the NIH Clinical Center for neoadjuvant treatment.
  • Participants will be randomized to receive either DC (Arm 1) or DCP (Arm 2) in the neoadjuvant setting. DC is three cycles of intravenous cisplatin plus docetaxel, administered every 21 days. PRGN-2009 is 4 doses of subcutaneous vaccination administered on Day -7 of Cycle 1, and Day 11 of Cycles 1, 2, and 3. Participants will be stratified at registration for stage (I or II).
  • Participants will undergo pre- and post-treatment Positron Emission Tomography (PET) / Computed Tomography (CT) and measurement of circulating cell-free HPV DNA.
  • Participants will return to the community to receive standard-of-care surgery. The need for pathology-indicated, risk-stratified PORT will be determined per standard of care.
  • Pathologic responses and follow-up to assess swallow function, QOL, hearing function, and recurrence-free survival will take place at the NIH Clinical Center.
03

Conditions studied

  • Squamous Cell Carcinoma of the Head and Neck
  • Oropharynx
  • Human Papillomavirus Viruses
  • Drug Therapy
  • Cancer Vaccine

Keywords

  • Neoadjuvant Chemotherapy
  • Oropharynx Cancer
  • Human Papillomavirus
  • Therapeutic Vaccine
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed surgically resectable newly diagnosed stage I (cT1-2, N0-1) or II (T1-3, N0-2), M0 oropharyngeal squamous cell carcinoma. Note: Pathological report of cancer diagnosis may be from the primary tumor or from a cervical lymph node.
  • History of HPV-positive status determined by a standard-of-care HPV testing. Note: All participants with high-risk HPV serotypes are eligible.
  • Age >= 18 years.
  • performance status \<= 2.
  • Individuals who smoke currently must smoke \<10 pack years. Note: Former smokers with any pack-year history are eligible if quit smoking >10 years before study treatment initiation. Former smokers who quit \<10 years before study treatment initiation must have smoked \<10 pack years.
  • Planned for cancer removal surgery per standard of care (SOC) and individual had agreed for the cancer removal surgery.

    • Individuals must have adequate organ and marrow function as defined below:
    • (ANC) >= 1.5 x 10\^9/L
    • (Hgb) >= 9.0 g/dL
    • count >= 100 x 10\^9/L
    • Creatinine \<= 1.2 x (ULN) OR calculated >=55 mL/min/1.73m\^2 by Cockcroft-Gault formula
  • Total \<= 1 x ULN, or \<= 3 x ULN in patients with known or suspected Gilbert's Syndrome
  • (ALT) \<= 1.5 x ULN
  • Aspartate aminotransferase (AST) \<= 1.5 x ULN
  • Individuals serologically positive for (HIV) must:

    • be on effective anti-retroviral therapy for at least 4 weeks; and
    • have undetectable viral load; and
    • have the >=200 cells/microL; and
    • have no reported opportunistic infections or Castleman s disease within 12 months prior to study treatment initiation
  • Individuals serologically positive for virus (HCV) or virus (HCB) must have an undetectable viral load.
  • Individuals of (IOCBP) must agree to use a highly effective method of (hormonal, intrauterine device (IUD), surgical sterilization, abstinence) for the duration of the study treatment and up to 2 months after the last dose of PRGN-2009 and an effective method of contraception (barrier, hormonal, intrauterine device (IUD), surgical sterilization, abstinence) for 14 months after the last dose of cisplatin/docetaxel. Note: IOCBP is defined as any woman who has experienced menarche and has not had a hysterectomy or bilateral oophorectomy or is not (amenorrheic 12 months or more following cessation of exogenous hormonal treatments; if \<50 years old and need follicle stimulating hormone [FSH] in the post-menopausal range).

Men must agree to use a highly effective method of contraception (surgical sterilization, abstinence) for the duration of the study treatment and up to 2 months after the last dose of PRGN-2009 and an effective method of contraception (barrier, surgical sterilization, abstinence) for the duration of the study treatment and up to 11 months after the last dose of the study drug(s). We also will recommend men on treatment with PRGN-2009 with female partners of childbearing potential ask female partners to be on highly effective birth control (hormonal, intrauterine device (IUD), surgical sterilization) during PRGN-2009 treatment and 2 months after that.

  • Breastfeeding individuals must be willing to discontinue breastfeeding from study treatment initiation through 2 months after the last dose of the study drug(s).
  • Individuals must have a tumor site that is amenable to and be willing to undergo pre- treatment biopsy for research purposes.
  • Individuals must be willing to undergo pre-treatment PET/CT imaging study.
  • The ability of an individual to understand and the willingness to sign a written document.

Exclusion criteria

EXCLUSION CRITERIA:

  • Peripheral motor or sensory neuropathy > Grade 2 per (CTCAE) v.5 at screening.
  • Prior therapy with an drug, , chemotherapy, immunotherapy, or any prior radiotherapy (except for palliative bone-directed therapy) within 4 weeks prior to the first study drug administration. Note: Participants may continue hormonal therapy in the setting of a definitively treated cancer (e.g., breast).
  • Prior therapy with any medications or substances that are moderate or strong inducers or moderate or strong inhibitors of cytochrome P450 () https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#table2-2,table3-3,table5-2 within 2 weeks prior to the first study drug administration.
  • History of allergic reactions attributed to compounds of similar chemical or biological composition to drugs used in the study.
  • Systemic (intravenous or oral) (except for physiologic doses of corticosteroids, i.e., \<= the equivalent of prednisone 10 mg/day) or other immunosuppressors such as azathioprine or cyclosporin A within 1 week prior to study treatment initiation. Note: Glucocorticoids as premedication for contrast-enhanced studies are allowed.
  • Second active within the previous 2 years except for indolent or locally curable malignancy that is currently considered cured and/or does not require an additional standard of care treatment, such as, but not limited to, cutaneous basal or squamous cell carcinoma, superficial bladder cancer, or cervical carcinoma in situ, or an incidental histological finding of prostate cancer or differentiated thyroid cancer.
  • Prior allogenic tissue/solid organ transplant.
  • History of heart failure.
  • Positive beta-human chorionic gonadotropin (beta-HCG) serum or urine pregnancy test performed in females of at screening.
  • Uncontrolled intercurrent illness or medical condition(s) evaluated by medical history and physical exam or situations that are not stable (e.g., recent hospitalization, Emergency Room visit or undergoing medication changes) that would potentially increase risk for the participant.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Arm 1

    DC (docetaxel + cisplatin)

    Drug: Docetaxel · Drug: Cisplatin

  • Experimental
    Arm 2

    DCP (docetaxel + cisplatin + PRGN-2009)

    Drug: Docetaxel · Drug: Cisplatin · Drug: PRGN-2009

Interventions

06

What researchers measure

Primary outcomes

  1. Determine the rate of pCR with NAC (DC) alone or in combination with PRGN-2009 (DCP) in participants with newly diagnosed HPV-associated OPSCC

    The pCR rates will be determined on each arm and will be reported along with a 95% confidence interval. The two rates will be compared using a one-sided Fisher s exact test.

    Time frame: 6 months

Secondary outcomes

  1. Determine the toxicity observed with DC and DCP

    Safety will be evaluated by determining the frequency of adverse events among treated participants and reporting the results, by maximum grade of event and type of toxicity noted. Tolerability will be recorded in the form of number of participants that discontinued treatment, had a delay in any study treatment or a DC dose reduction, and any study drug-related surgical delays.

    Time frame: Day 1 (all arms) and day 11 (Arm 2 only) of every cycle and Day -7 of C1 (Arm 2 only), and at Safety Follow-Up visit which occurs 14 (+14) days after the study agent (s) was/were last administered. 3-month follow-up visit and beyond.

  2. Determine 2-year and 5-year recurrence-free survival (RFS) observed with DC and DCP

    Recurrence-free survival will be determined using the Kaplan-Meier method for each arm, with recurrence or death without recurrence considered as events. The two-year and five-year recurrence-free survival values will be reported along with a 95% two-sided confidence interval for each arm. The two curves will also be compared using a two-tailed log-rank test.

    Time frame: 3, 6, 12, 24 months after surgery per SOC until recurrence.

07

Study locations

1 of 1 sites recruiting
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
    Recruiting
    • National Cancer Institute Referral Office · Contact888-624-1937
08

References and documents

Individual participant data

Plan to share: Yes — All collected IPD will be shared.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: This study will comply with the NIH Data Management and Sharing (DMS) Policy, which applies to all new and ongoing NIH-funded research in the IRP, as of January 25, 2023, that is associated with a ZIA, with a clinical protocol that undergoes scientific review and/or will involve genomic data sharing.

Access criteria: Data from this study may be requested by contacting the PI.

09

Timeline

5 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Jan 2028, 43 months after the start.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 43 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2024
First posted
Jan 25, 2024
StartActual
Jun 10, 2024
Primary completionEst.
Jan 10, 2028
CompletionEst.
Jan 10, 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Recruiting
changed Oct 16, 2026
Sites
National Institutes of Health Clinical Center is now Recruiting
Oct 16, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 13, 2026
  • EditedDetermine 2-year and 5-year recurrence-free survival (RFS) observed with DC and DCPTime frame: 3, 6, 12, 24 months after surgery per SOC until recurrence.
What changed on Oct 15, 2026
  • DescriptionDetermine 2-year and 5-year recurrence-free survival (RFS) observed with DC and DCP: how it is measured was reworded
across 2 updates, Oct 13, 2026 – Oct 15, 2026
Contact
Study contact now listed: added m•••@nih.gov · •••3391; added c•••@nih.gov · •••4216. See the current contact
Oct 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • National Institutes of Health Clinical Center · Bethesda, United StatesContact added •••1937
Oct 16, 2026
Show all 5 updates
  1. Nov 16, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 19, 2026
    Minor edits only
    + 1 other change: verification date
  3. Oct 16, 2026
    Active, not recruiting→Recruiting
    National Institutes of Health Clinical Center is now Recruiting
    Contact Study contact now listed: added m•••@nih.gov · •••3391; added c•••@nih.gov · •••4216. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • National Institutes of Health Clinical Center · Bethesda, United StatesContact added •••1937
    + 2 other changes: verification date and references
  4. Oct 15, 2026
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionDetermine 2-year and 5-year recurrence-free survival (RFS) observed with DC and DCP: how it is measured was reworded
    + 1 other change: verification date
  5. Oct 13, 2026
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedDetermine 2-year and 5-year recurrence-free survival (RFS) observed with DC and DCPTime frame: 3, 6, 12, 24 months after surgery per SOC until recurrence.
    + 1 other change: description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06223568
Responsible party
Sponsor
First posted
Jan 25, 2024
Start date
Jun 10, 2024
Primary completion
Jan 10, 2028 (estimated)
Completion
Jan 10, 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Melissa L Wheatley
Contact
melissa.wheatley@nih.gov
(240) 858-3391
Clint T Allen, M.D.
Contact
clint.allen@nih.gov
(301) 402-4216
Clint T Allen, M.D.
principal investigator · National Cancer Institute (NCI)

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gorilla-derived Adenovirus-expressing HPV-16/18 E6/E7 Vaccine

Start the discussion